Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Abusing psychoactive substances, such as ADHD medication, cannabis, and nicotine, not only creates an addiction but can impact mental distress.


College Students Who Abuse Psychoactive Substances Might Land in a “Vicious Loop”

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

Children with Eczema Struggle More with Comorbid ADHD Symptoms

Understanding the Link Between Substance Use and Psychiatric Symptoms, with Randi Schuster, PhD

A new survey study of high schoolers found alcohol, cannabis, and nicotine were linked to significant, moderate dose-dependent associations with worse symptoms of depression, anxiety, ADHD, general mental health, as well as suicidal thoughts.

Single Substance Not Linked to Single Psychiatric Symptom in Adolescents

Young adults aged 18 – 19 are the age range who discontinues ADHD medication the most, according to a new study.

Young Adults, Adolescents Discontinue ADHD Medication More Than Children

In a new study, patients with ADHD on cannabis-based medicinal products had significant improvements for anxiety, sleep quality, and health-related quality of life.

Cannabis Treatment Linked to Improving Quality of Life in ADHD Patients

At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.

Long-Term ADHD Medication Use Linked to Potential Risk of Cardiovascular Diseases

Adults with ADHD have greater reduction of symptoms with regulatory licensed doses of stimulants than unlicensed doses.

Unlicensed Stimulant Doses in Adult ADHD Barely Reduce Symptoms Compared to Licensed Doses

Two pivotal phrase 3 centanafadine trials show positive outcomes for children and adolescents with ADHD.


Centanafadine Shows Promise in Phase 3 Trials for Adolescent ADHD 

The rates of pediatric and adolescent treatment for depression, anxiety, ADHD, and behavior disorders vary by age, income level, and region.

Mental Disorders Treatment Rates Remain Low Among Children and Adolescents

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.